Blood viscosity, glycaemic control and retinopathy in insulin-dependent diabetes. 1982

P Y Poon, and T L Dornan, and C Orde-Peckar, and R Mullins, and A J Bron, and R C Turner

1. In a cross-sectional study, 32 insulin-treated diabetic patients had elevated low shear (27.1 vs 22.1 mPa s, P less than 0.05) and high shear blood compared with 10 non-diabetic controls. After correction to 45% packed cell volume, the abnormality had a tendency to be greater in patients with proliferative (mean low shear viscosity, 30.8 mPa s) than background (29.2 mPa s) or nil/minimal retinopathy (27.6 mPa s, 0.05 less than P less than 0.97, permutational trend test). 2. The fibrinogen levels were higher in the diabetic group (P less than 0.05) and correlated with the low shear blood viscosity (rs = 0.38, P less than 0.05). 3. In a prospective study, 74 insulin-treated diabetic patients with background retinopathy were randomized into two groups. Thirty-six patients were on attempted improved therapy (A group); in these the mean glycosylated haemoglobin (Hb A1c) fell within 1 year (11.6 to 10.1%, P less than 0.001). both the corrected low shear blood and plasma viscosity fell similarly (P less than 0.001). The fall was greater than in those patients who were kept on usual therapy (U group) and whose glycosylated haemoglobin did not change significantly (11.7 to 11.4% over the year. 4. The effect of diabetes on blood viscosity may not be a direct pathological factor, as the same increased viscosity would be produced by a mean increase of 1.7% in packed cell volume, compared with a population range of 14% packed cell volume.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D001809 Blood Viscosity The internal resistance of the BLOOD to shear forces. The in vitro measure of whole blood viscosity is of limited clinical utility because it bears little relationship to the actual viscosity within the circulation, but an increase in the viscosity of circulating blood can contribute to morbidity in patients suffering from disorders such as SICKLE CELL ANEMIA and POLYCYTHEMIA. Blood Viscosities,Viscosities, Blood,Viscosity, Blood
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D003930 Diabetic Retinopathy Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION. Diabetic Retinopathies,Retinopathies, Diabetic,Retinopathy, Diabetic
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D006442 Glycated Hemoglobin Products of non-enzymatic reactions between GLUCOSE and HEMOGLOBIN (occurring as a minor fraction of the hemoglobin of ERYTHROCYTES.) It generally refers to glycated HEMOGLOBIN A. Hemoglobin A1c (Hb A1c) is hemoglobin A with GLYCATION on a terminal VALINE of the beta chain. Glycated hemoglobin A is used as an index of the average blood sugar level over a lifetime of erythrocytes. Fructated Hemoglobins,Glycohemoglobin,Glycohemoglobin A,Glycohemoglobins,Glycosylated Hemoglobin A,Hb A1c,HbA1,Hemoglobin A(1),Hemoglobin A, Glycosylated,Glycated Hemoglobin A,Glycated Hemoglobin A1c,Glycated Hemoglobins,Glycosylated Hemoglobin A1c,Hb A1,Hb A1a+b,Hb A1a-1,Hb A1a-2,Hb A1b,Hemoglobin, Glycated A1a-2,Hemoglobin, Glycated A1b,Hemoglobin, Glycosylated,Hemoglobin, Glycosylated A1a-1,Hemoglobin, Glycosylated A1b,A1a-1 Hemoglobin, Glycosylated,A1a-2 Hemoglobin, Glycated,A1b Hemoglobin, Glycated,A1b Hemoglobin, Glycosylated,Glycated A1a-2 Hemoglobin,Glycated A1b Hemoglobin,Glycosylated A1a-1 Hemoglobin,Glycosylated A1b Hemoglobin,Glycosylated Hemoglobin,Hemoglobin A, Glycated,Hemoglobin A1c, Glycated,Hemoglobin A1c, Glycosylated,Hemoglobin, Glycated,Hemoglobin, Glycated A1a 2,Hemoglobin, Glycosylated A1a 1,Hemoglobins, Fructated,Hemoglobins, Glycated

Related Publications

P Y Poon, and T L Dornan, and C Orde-Peckar, and R Mullins, and A J Bron, and R C Turner
May 1986, Journal of the Royal Society of Medicine,
P Y Poon, and T L Dornan, and C Orde-Peckar, and R Mullins, and A J Bron, and R C Turner
November 1997, Diabetic medicine : a journal of the British Diabetic Association,
P Y Poon, and T L Dornan, and C Orde-Peckar, and R Mullins, and A J Bron, and R C Turner
October 1994, British journal of anaesthesia,
P Y Poon, and T L Dornan, and C Orde-Peckar, and R Mullins, and A J Bron, and R C Turner
August 1997, Diabetic medicine : a journal of the British Diabetic Association,
P Y Poon, and T L Dornan, and C Orde-Peckar, and R Mullins, and A J Bron, and R C Turner
February 1997, Diabetic medicine : a journal of the British Diabetic Association,
P Y Poon, and T L Dornan, and C Orde-Peckar, and R Mullins, and A J Bron, and R C Turner
August 1992, Postgraduate medical journal,
P Y Poon, and T L Dornan, and C Orde-Peckar, and R Mullins, and A J Bron, and R C Turner
February 1989, BMJ (Clinical research ed.),
P Y Poon, and T L Dornan, and C Orde-Peckar, and R Mullins, and A J Bron, and R C Turner
April 1993, Scandinavian journal of clinical and laboratory investigation,
P Y Poon, and T L Dornan, and C Orde-Peckar, and R Mullins, and A J Bron, and R C Turner
January 1988, Diabete & metabolisme,
P Y Poon, and T L Dornan, and C Orde-Peckar, and R Mullins, and A J Bron, and R C Turner
October 1995, Diabetes research and clinical practice,
Copied contents to your clipboard!